Abstracts Archive - Page 1306 of 2425 - ACR Meeting Abstracts

Abstract Number: 1507 • 2017 ACR/ARHP Annual Meeting
Comparison of the Clinical and Imaging Arms of the Assessment of Spondyloarthritis International Society Classification Criteria and Parameters of Objective Inflammation in Patients with Non-Radiographic Axial Spondyloarthritis
Robert B.M. Landewé¹, Joachim Sieper², Atul A. Deodhar³, Helena Marzo-Ortega⁴, Robert G. Lambert⁵, Mei Li⁶, Xin Wang⁶ and Jaclyn K. Anderson⁶, ¹University of Amsterdam, Amsterdam, Netherlands, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Oregon Health & Science University, Portland, OR, ⁴NIHR LBRC, Leeds Teaching Hospitals Trust and LIRMM, University of Leeds, Leeds, United Kingdom, ⁵University of Alberta, Edmonton, AB, Canada, ⁶AbbVie Inc., North Chicago, IL
Background/Purpose: Assessment of SpondyloArthritis international Society (ASAS) recommendations for use of TNF inhibitors (TNFi) in axial SpA include active disease and a positive expert opinion,…
Abstract Number: 1508 • 2017 ACR/ARHP Annual Meeting
Validation of Self-Reported Inflammatory Back Pain Score Compared to Rheumatology Consultation in University Students
Nelly Ziade¹, Fouad Fayad¹ and Lea el-Khoury², ¹Rheumatology, Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, ²Saint-Joseph University, Beirut, Lebanon
Validation of self-reported inflammatory back pain score compared to rheumatology consultation in university students Background/Purpose: Low Back Pain (LBP) is a major public health problem affecting…
Abstract Number: 1509 • 2017 ACR/ARHP Annual Meeting
Similarities and Differences between Non-Radiographic and Radiographic Axial Spondyloarthritis
Denis Poddubnyy¹, Robert D Inman², Joachim Sieper¹, Servet Akar³, Santiago Muñoz-Fernández⁴ and Maja Hojnik⁵, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁴Hospital Universitario Infanta Sofía, Universidad Europea, Mardid, Spain, ⁵AbbVie, Ljubljana, Slovenia
Background/Purpose: Differences between non-radiographic and radiographic axial spondyloarthritis (axSpA) – such as a higher prevalence of females and lower level of acute phase reactants in…
Abstract Number: 1510 • 2017 ACR/ARHP Annual Meeting
Similarities and Differences between Osteitis Condensans Ilii and Axial Spondyloarthritis Patients Presenting with Chronic Back Pain in a Rheumatology Setting
Henning Weineck¹, Joachim Listing², Torsten Diekhoff¹, Kay-Geert Hermann¹, Joachim Sieper¹ and Denis Poddubnyy^1,2, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: Osteitis condensans ilii (OCI) is regarded as a non-inflammatory disorder, which is considered to be induced by mechanical stress (e.g., by pregnancy and delivery).…
Abstract Number: 1511 • 2017 ACR/ARHP Annual Meeting
Real-Life Performance of the ASAS Health Index in Routine Care of Patients with Spondyloarthritis
Uta Kiltz, Thomas Wiatr, Xenofon Baraliakos, Kirill Fedorov and Jürgen Braun, Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: The ASAS Health Index (ASAS HI) have been developed to measure health and impairment in functioning in patients with spondyloarthritis (SpA). Its measurement properties…
Abstract Number: 1512 • 2017 ACR/ARHP Annual Meeting
Is Sacroiliac Imaging the All-Decisive Factor in the Diagnosis of Early Axial Spondyloarthritis? Data from the Spondyloarthritis Caught Early (SPACE) Cohort
Zineb Ez-Zaitouni¹, Robert B.M. Landewé², Miranda van Lunteren¹, Pauline Bakker¹, Karen M Fagerli³, Roberta Ramonda⁴, Lennart TH Jacobsson⁵, Désirée van der Heijde⁶ and Floris van Gaalen⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology Unit, University of Padova, Padova, Italy, ⁵Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Imaging of the sacroiliac joints plays a pivotal role in the recognition of axSpA. However, interpretation of imaging is challenging and has led to…
Abstract Number: 1513 • 2017 ACR/ARHP Annual Meeting
Clinical Characteristics and Peripheral Joint Involvement at the Time of Diagnosis of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe
Atul A. Deodhar¹, Theresa Hunter², David Sandoval Calderon³, Steve Lobosco⁴, Rachel Moon⁴ and Gary Milligan⁵, ¹Oregon Health & Science University, Portland, OR, ²Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianapolis, IN, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Adelphi Real World, Macclesfield,, United Kingdom
Background/Purpose: Timely identification of nr-axSpA may lead to earlier intervention to reduce symptoms, improve function, and reduce disease burden. The purpose of this study was…
Abstract Number: 1514 • 2017 ACR/ARHP Annual Meeting
Phenotype Differences in HLA-B27 Positive Versus Negative Patients with Ankylosing Spondylitis in a Population That Show Relatively Weaker Association with HLA-B27
Handan Yarkan¹, Zhixiu Li², Gokce Kenar³, Sedat Capar⁴, Fernur Çapa⁵, Rudi Steffensen⁶, Servet Akar⁷, Dilek Solmaz⁸, Pınar Cetin⁹, Berrin Zengin³, Erika de Guzman¹⁰, Katie Cremin², Gerçek Can¹¹, Zeynep Yüce⁵, Ismail Sari¹², Fatos Onen¹³, Matt Brown² and Nurullah Akkoc¹⁴, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, ³Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ⁴Statistics, Dokuz Eylul University School of Medicine, Izmir, Turkey, ⁵Department of Molecular Medicine, Dokuz Eylül University Health Sciences Institute, IZMIR, Turkey, ⁶Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark, ⁷Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁸Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, izmir, Turkey, ⁹Rheumatology, Dokuz Eylul University Faculty of Medicine, izmir, Turkey, ¹⁰Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Austria, ¹¹TURKBIO, İzmir, Turkey, İzmir, Turkey, ¹²Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ¹³TURKBIO, İzmir, Turkey, Izmir, Turkey, ¹⁴Rheumatology, Private Practice, Rheumatology, İzmir, Turkey
Background/Purpose: The association of HLA-B*27 and ankylosing spondylitis (AS) is relatively weak in some populations. The aim of this study is to compare the clinical…
Abstract Number: 1515 • 2017 ACR/ARHP Annual Meeting
Improvements in Enthesitis Scores with Certolizumab Pegol Treatment in Males and Females with Active Axial Spondyloarthritis Are Maintained to Week 204
Maxime Dougados¹, Philip J Mease², Joachim Sieper³, Peter C. Taylor⁴, Natasha de Peyrecave⁵, Tommi Nurminen⁶ and Jürgen Braun⁷, ¹Rheumatology Department, Paris-Descartes University and Cochin Hospital, Paris, France, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Charité University Hospital, Berlin, Germany, ⁴Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim, Germany, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA), characterized by spinal inflammation, is also associated with extra-spinal manifestations including inflammation of the entheses (enthesitis). Enthesitis is equally prevalent throughout…
Abstract Number: 1516 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Certolizumab Pegol in Patients with Uveitis Associated to Spondyloarthritis Refractory to Other Tumour Necrosis Factor Inhibitors
M. Victoria Hernández¹, Marina Mesquida¹, Victor Llorens², Maite Sainz de la Maza², Ricardo Blanco³, Vanesa Calvo⁴, Olga Maiz⁵, Ana Blanco⁶, Ana Urruticoechea-Arana⁷, Juan Ramon De Dios⁸, Pilar Ahijado-Guzman⁹, Enrique Judez¹⁰, Patricia Tejón¹¹, M Soledad Peña¹², Francisca Sivera¹³, Alfredo Adan¹ and Raimon Sanmarti¹⁴, ¹Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ²Ophthalmology Department. Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Rheumatology Department. Hospital Universitario Marqués de Valdecilla., Santander, Spain, ⁵Hospital Donostia. Spain, San Sebastian, Spain, ⁶Ophthalmology Department. Hospital Donostia, San Sebastian, Spain, ⁷Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ⁸Rheumatology Department. Hospital Universitario de Araba, Vitoria, Spain, ⁹Rheumatology Unit. Fuenlabrada’s Hospital, Madrid, Madrid, Spain, ¹⁰Rheumatology Department. Hospital de Albacete, Albacete, Spain, ¹¹Rheumatology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹²Ophtalmology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹³Sección de Reumatología, Hospital General Universitario de Elda., Elda, Spain, ¹⁴Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: Uveitis is a common extra-articular manifestation in patients with spondyloarthritis (SpA) requiring, in most severe cases, the use of biological therapy, especially tumour necrosis…
Abstract Number: 1517 • 2017 ACR/ARHP Annual Meeting
Effectiveness and Retention Rate of Certolizumab Pegol in Spondyloarthritis. Real Life Data
Rosa Expósito¹, Carlos M Gonzalez², Rosa García-Portales³, Ana Urruticoechea-Arana⁴, Jose Ramon Lamua⁵, Maria del Pilar Navarro⁶, José Santos Rey Rey⁷ and Manuel Fernández⁸, ¹Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ²Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ³Rheumatology, Hospital Virgen de la Victoria, Málaga, Spain, ⁴Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ⁵Hospital del Henares, Madrid, Spain, ⁶Hospital de Fuenlabrada, Fuenlabrada, Spain, ⁷Hospital Virgen de la Salud, Toledo, Spain, ⁸H. Guadalajara, Guadalajara, Spain
Background/Purpose: Certolizumab pegol (CZP) is available for patients with spondyloarthritis (SpA), including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axialSpA). CZP has a different molecular…
Abstract Number: 1518 • 2017 ACR/ARHP Annual Meeting
Certolizumab Pegol Effectiveness and Retention Rate in Psoriatic Arthritis. Real Life Data
Arantxa Conesa¹, Manuel Fernández², Rosa Expósito³, Jose Campos⁴, Jose Ramon Lamua⁵, Maria del Pilar Navarro⁶, Paula Rubio-Muñoz⁷, Pilar Ahijado-Guzman⁸ and Carlos M Gonzalez⁹, ¹Hospital Clínico Universitario de Valencia, Valencia, Spain, ²Hospital Universitario de Guadalajara, Guadalajara, Spain, ³Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ⁴Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁵Hospital del Henares, Madrid, Spain, ⁶Hospital de Fuenlabrada, Fuenlabrada, Spain, ⁷Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁸Rheumatology Unit. Fuenlabrada’s Hospital, Madrid, Madrid, Spain, ⁹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: To evaluate the effectiveness and safety of Certolizumab Pegol (CZP) in a real word setting in Psoriatic Arthritis (PsA) patients. Methods: Multicentric cohort of…
Abstract Number: 1519 • 2017 ACR/ARHP Annual Meeting
Certolizumab Pegol Effectiveness in Radiographic and Non-Radiographic Axial Spondyloarthritis. a Natiowide Study
Carlos M Gonzalez¹, Rosa Expósito², Rosa García-Portales³, Ana Urruticoechea-Arana⁴, Jose Ramon Lamua⁵, Maria del Pilar Navarro⁶, José Santos Rey Rey⁷, Manuel Fernández⁸ and Mercedes Morcillo⁹, ¹Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ²Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ³Rheumatology, Hospital Virgen de la Victoria, Málaga, Spain, ⁴Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ⁵Hospital del Henares, Madrid, Spain, ⁶Hospital de Fuenlabrada, Fuenlabrada, Spain, ⁷Hospital Virgen de la Salud, Toledo, Spain, ⁸H. Guadalajara, Guadalajara, Spain, ⁹Rheumatology, Hospital El Escorial, San Lorenzo de el Escorial, Spain
Background/Purpose: Certolizumab pegol (CZP) is a PEGylated Fab’ fragment of a humanized anti-TNF antibody with high affinity to TNF. RAPID-axSpA trial investigated the efficacy and…
Abstract Number: 1520 • 2017 ACR/ARHP Annual Meeting
Golimumab Retention Rate in Patients with Spondyloarthitis. Differences between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Belen Serrano¹, Carlos M Gonzalez², Roberto González³, Julia Martínez-Barrio⁴, Juan Gabriel Ovalles-Bonilla⁵, Juan Carlos Nieto², Iustina Janta², Larissa Valor³, Francisco Javier López Longo⁶ and Indalecio Monteagudo², ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Genoa, Italy, ²Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ⁴Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ⁶Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The efficacy of Golimumab (GLM) treatment in spondyloarthritis (SpA) has been widely documented. The aim of this study was to analize the long-term retention…
Abstract Number: 1521 • 2017 ACR/ARHP Annual Meeting
Impact of Time Since Diagnosis, Age, and Number of Prior Non-Steroidal Anti-Inflammatory Drugs on 52-Week Clinical Response to Adalimumab in Patients with Ankylosing Spondylitis
Joachim Sieper¹, Atul A. Deodhar², Maja Hojnik³, Ying Zhang⁴ and Maxime Dougados⁵, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Oregon Health & Science University, Portland, OR, ³AbbVie, Ljubljana, Slovenia, ⁴AbbVie Inc., North Chicago, IL, ⁵René Descartes University and Hôpital Cochin, Paris, France
Background/Purpose : Ankylosing spondylitis (AS) patients (pts) were found to respond better to TNF inhibitors (TNFi) if treated early in the disease course.1 The actual…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].